• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.81% Nasdaq Up1.48%

    BioCryst Pharmaceuticals, Inc. (BCRX)

    1.71 Up 0.05(3.01%) 2:50PM EST - Nasdaq Real Time Price
    ProfileGet Profile for:
    BioCryst Pharmaceuticals, Inc.
    4505 Emperor Boulevard
    Suite 200
    Durham, NC 27703
    United States - Map
    Phone: 919-859-1302
    Fax: 919-859-1314
    Website: http://www.biocryst.com

    Index Membership:N/A
    Full Time Employees:50

    Business Summary 

    BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza; BCX4161, an oral serine protease inhibitor, which is in Phase II clinical trial for hereditary angioedema (HAE); and BCX7353 and other second generation HAE compounds, which are oral serine protease inhibitors that are in preclinical trial for HAE. The company’s product candidates also comprise BCX4430, an RNA dependent-RNA polymerase inhibitor that is in Phase I clinical trial for treating Filoviruses, including Ebola and Marburg viruses; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on BioCryst Pharmaceuticals, Inc.

    Corporate Governance 
    BioCryst Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Feb 1, 2016 is 7. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Jon P. Stonehouse , 55
    Chief Exec. Officer, Pres and Exec. Director
    Mr. Thomas R. Staab II, CPA, 48
    Chief Financial Officer, Principal Accounting Officer, Sr. VP and Treasurer
    Ms. Alane P. Barnes , 50
    VP, Gen. Counsel and Corp. Sec.
    Dr. William P. Sheridan MBBS, 61
    Chief Medical Officer and Sr. VP
    Dr. Yarlagadda S. Babu Ph.D., 63
    Sr. VP of Drug Discovery
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders